Little Green Pharma Future Growth

Future criteria checks 1/6

Little Green Pharma is forecast to grow earnings and revenue by 46% and 17% per annum respectively. EPS is expected to grow by 47.4% per annum. Return on equity is forecast to be -1% in 3 years.

Key information

46.0%

Earnings growth rate

47.4%

EPS growth rate

Pharmaceuticals earnings growth	28.2%
Revenue growth rate	17.0%
Future return on equity	-1.0%
Analyst coverage	Low
Last updated	17 Apr 2024

Recent future growth updates

Recent updates

Statutory Earnings May Not Be The Best Way To Understand Little Green Pharma's (ASX:LGP) True Position

Sep 06

What Type Of Shareholders Make Up Little Green Pharma Ltd's (ASX:LGP) Share Registry?

Feb 11

Earnings and Revenue Growth Forecasts

ASX:LGP - Analysts future estimates and past financials data (AUD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2026	36	0	1	2	1
3/31/2025	30	-3	-2	-1	1
3/31/2024	26	0	-2	1	1
9/30/2023	23	-3	-5	-2	N/A
6/30/2023	22	-6	-8	-4	N/A
3/31/2023	20	-9	-12	-7	N/A
3/31/2022	14	-24	-33	-23	N/A
12/31/2021	11	13	-21	-14	N/A
9/30/2021	9	18	-14	-10	N/A
6/30/2021	7	22	-6	-5	N/A
3/31/2021	6	9	-7	-4	N/A
12/31/2020	5	-3	-7	-2	N/A
9/30/2020	4	-6	-10	-4	N/A
6/30/2020	2	-9	-13	-6	N/A
3/31/2020	2	-9	-11	-6	N/A
12/31/2019	1	-9	-8	-5	N/A
9/30/2019	1	-7	-6	-4	N/A
6/30/2019	0	-6	-4	-3	N/A
6/30/2018	0	-4	-2	-2	N/A
6/30/2017	0	0	N/A	0	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: LGP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: LGP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: LGP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: LGP's revenue (17% per year) is forecast to grow faster than the Australian market (5.2% per year).

High Growth Revenue: LGP's revenue (17% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: LGP is forecast to be unprofitable in 3 years.

Little Green Pharma Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Price target decreased to AU$1.04

Price target decreased to AU$1.04

Recent updates

Now 22% undervalued after recent price drop

Little Green Pharma (ASX:LGP) Has Debt But No Earnings; Should You Worry?

New major risk - Financial position

Little Green Pharma Ltd, Annual General Meeting, Feb 21, 2024

First half 2024 earnings released: AU$0.007 loss per share (vs AU$0.004 loss in 1H 2023)

Not Many Are Piling Into Little Green Pharma Ltd (ASX:LGP) Just Yet

Little Green Pharma Limited Announces Australian Clinical Study Finds Medicinal Cannabis Significantly Improves Pain, Quality of Life, Moderate-Severe Anxiety and Depression

Little Green Pharma Announces CEO Changes, Effective 29 August 2023

Full year 2023 earnings released: AU$0.034 loss per share (vs AU$0.10 loss in FY 2022)

Now 20% undervalued after recent price drop

Full year 2023 earnings released: AU$0.034 loss per share (vs AU$0.10 loss in FY 2022)

A Look At The Intrinsic Value Of Little Green Pharma Ltd (ASX:LGP)

Little Green Pharma Ltd, Annual General Meeting, Jan 31, 2023

Little Green Pharma Ltd. Obtains Ethics Approval for its Proposed Multi-Site, Placebo-Controlled Pharmacokinetic and Phase III Efficacy and Safety Trial

Little Green Pharma Ltd Significantly Expands Flower Portfolio

Little Green Pharma Ltd Provides Update on French Trial Extension

Less than half of directors are independent

Little Green Pharma Ltd Appoints Beatriz Vicén Banzo as Non-Executive Director

Little Green Pharma Ltd, Annual General Meeting, Aug 12, 2022

Price target decreased to AU$1.04

Insufficient new directors

Executive Director exercised options to buy AU$1.7m worth of stock.

Insufficient new directors

Insufficient new directors

Little Green Pharma Ltd Secures First Registration for Locally Produced Cannabis Medicine in Denmark

Price target decreased to AU$1.04

Full year 2021 earnings released: EPS AU$0.16 (vs AU$0.073 loss in FY 2020)

Statutory Earnings May Not Be The Best Way To Understand Little Green Pharma's (ASX:LGP) True Position

Full year 2021 earnings released: EPS AU$0.16 (vs AU$0.073 loss in FY 2020)

Little Green Pharma Ltd (ASX:LGP) acquired GACP cultivation and GMP licensed medicinal cannabis asset in Denmark for CAD 20 million.

Little Green Pharma Ltd Receives Firm Purchase Order from Deutsche Medizinalcannabis Gmbh

Little Green Pharma Ltd Delivers First French Shipment

First half 2021 earnings released: EPS AU$0.004 (vs AU$0.077 loss in 1H 2020)

Little Green Pharma Ltd Announces Supply of Medicinal Cannabis Oil Products to Enrolled Patients as Well as Providing Funding for Study Costs for the QUality uality of Life Evaluation STudy

Little Green Pharma Ltd announced that it expects to receive AUD 22.1 million in funding

What Type Of Shareholders Make Up Little Green Pharma Ltd's (ASX:LGP) Share Registry?

Little Green Pharma Ltd Exports First Commercial Shipment

Little Green Pharma Ltd Announces it has Selected Primary Supplier of Medicinal Cannabis Oils for French National Trial of Medicinal Cannabis in Partnership Intsel Chimos

New 90-day high: AU$0.65

Little Green Pharma Ltd Announces TGA's final Decision to Both Down-Schedule Certain Medicinal Cannabidiol Products from Schedule 4 to Schedule 3

New 90-day high: AU$0.61

Little Green Pharma Ltd Provides Update on Its Export of the Largest Australian Commercial Shipment

New 90-day high: AU$0.36

Little Green Pharma Ltd Announces Post-Market Survey Test Results

New 90-day low - AU$0.31

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies